---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061538"
form_type: "8-K"
ticker: null
cik: "0001851194"
company_name: "Ventyx Biosciences, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:55:38.108709+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ventyx raises $100M in private placement; discloses securities class action lawsuit

## Summary
- Sold 11,174,000 shares at $8.95/share for gross proceeds ~$100M; led by Farallon, Cormorant, Deerfield, Redmile, Surveyor.
- Net proceeds to fund VTX3232, VTX2735, VTX002 clinical development and preclinical programs; cash runway extended into at least 2H 2026.
- Private placement expected to close on March 11, 2024, subject to customary conditions.
- Securities class action filed Mar 1 alleges misleading statements on VTX958 Phase 2 trial; company believes lawsuit without merit.

## SEC filing metadata
- accession: 0001193125-24-061538
- form_type: 8-K
- cik: 0001851194
- company_name: Ventyx Biosciences, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/d765460d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061538
- JSON: https://secwatch.observer/filing/0001193125-24-061538.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061538.txt

## Key facts
- Material Agreements
  Ventyx Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-03-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Purchasers
  - Effective: 2024-03-06
  source text: In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated March 6, 2024 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares that are not then registered on an effective registration statement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm
- Material Agreements
  Ventyx Biosciences, Inc. entered into Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $100.0 million (effective 2024-03-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain qualified institutional buyers and institutional accredited investors
  - Value: approximately $100.0 million
  - Effective: 2024-03-06
  source text: On March 6, 2024, Ventyx Biosciences, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.